LOGIN  |  REGISTER
Astria Therapeutics

Singular Genomics to Present at the Goldman Sachs Global Healthcare Conference

May 29, 2024 | Last Trade: US$12.85 0.47 3.80

SAN DIEGO, May 29, 2024 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and spatial multiomics technologies to empower researchers and clinicians, today announced plans to present at the Goldman Sachs 45th Annual Global Healthcare Conference in Miami, Florida.

Singular Genomics’ management is scheduled to participate in a fireside chat Wednesday, June 12, 2024, at 7:40 a.m. Pacific Time / 10:40 a.m. Eastern Time. Investors and other interested parties are invited to listen to a live and recorded webcast of the presentation at investor.singulargenomics.com in the Presentations & Events section.

About Singular Genomics Systems, Inc.

Singular Genomics is a life science technology company that develops next-generation sequencing and multiomics technologies. The commercially available G4® Sequencing Platform is a powerful, highly versatile benchtop genomic sequencer designed to produce fast and accurate results. In addition, the company is currently developing the G4X™ Spatial Sequencer, which will leverage Singular’s proprietary sequencing technology, applying it as an in situ readout for transcriptomics, proteomics and fluorescent H&E in tissue, with spatial context and on the same platform as the G4. Singular Genomics’ mission is to empower researchers and clinicians to advance science and medicine. Visit www.singulargenomics.com for more information.

Investor Contact
Philip Trip Taylor
Gilmartin Group
This email address is being protected from spambots. You need JavaScript enabled to view it.  

Media Contact
Matt Browning
This email address is being protected from spambots. You need JavaScript enabled to view it.

Viking Therapeutics

Stock Quote

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB